HC Wainwright Reaffirms "Buy" Rating for Alpha Tau Medical (NASDAQ:DRTS)

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Friday, Benzinga reports. They currently have a $9.00 target price on the stock. HC Wainwright's price target indicates a potential upside of 309.09% from the company's current price.

Separately, Piper Sandler reissued an "overweight" rating and issued a $7.00 target price on shares of Alpha Tau Medical in a report on Thursday, August 15th.

Alpha Tau Medical Stock Performance

Shares of DRTS traded down $0.05 on Friday, reaching $2.20. 16,747 shares of the stock traded hands, compared to its average volume of 32,232. The stock's 50-day moving average price is $2.25 and its 200-day moving average price is $2.39. The company has a debt-to-equity ratio of 0.07, a current ratio of 11.66 and a quick ratio of 11.60. The firm has a market cap of $153.28 million, a price-to-earnings ratio of -5.56 and a beta of 0.77. Alpha Tau Medical has a 12 month low of $1.75 and a 12 month high of $3.90.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.02. Equities analysts forecast that Alpha Tau Medical will post -0.48 EPS for the current fiscal year.

Hedge Funds Weigh In On Alpha Tau Medical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. USAdvisors Wealth Management LLC bought a new position in shares of Alpha Tau Medical in the first quarter valued at approximately $30,000. Aptus Capital Advisors LLC grew its holdings in shares of Alpha Tau Medical by 83.7% during the second quarter. Aptus Capital Advisors LLC now owns 21,945 shares of the company's stock worth $56,000 after purchasing an additional 10,000 shares during the last quarter. Financial Guidance Group Inc. grew its holdings in Alpha Tau Medical by 83.7% during the 2nd quarter. Financial Guidance Group Inc. now owns 21,945 shares of the company's stock worth $56,000 after acquiring an additional 10,000 shares during the last quarter. Caprock Group LLC acquired a new stake in Alpha Tau Medical in the 2nd quarter valued at about $59,000. Finally, Levin Capital Strategies L.P. raised its stake in shares of Alpha Tau Medical by 2.6% in the first quarter. Levin Capital Strategies L.P. now owns 338,764 shares of the company's stock worth $999,000 after acquiring an additional 8,641 shares during the last quarter. 2.65% of the stock is currently owned by institutional investors and hedge funds.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.